Daxor Corp (DXR)
8.35
+0.21
(+2.58%)
USD |
NASDAQ |
Dec 20, 16:00
8.35
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 40.41M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 4.38% |
| Valuation | |
| PE Ratio | 27.81 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 15.44 |
| Price to Book Value | 1.238 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0505 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 69.76% |
Profile
| Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions. |
| URL | https://www.daxor.com |
| Investor Relations URL | http://www.daxor.com/investors/ |
| HQ State/Province | Tennessee |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 25, 2025 (est.) |
| Last Earnings Release | Aug. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 05, 2018 |
Ratings
Profile
| Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions. |
| URL | https://www.daxor.com |
| Investor Relations URL | http://www.daxor.com/investors/ |
| HQ State/Province | Tennessee |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 25, 2025 (est.) |
| Last Earnings Release | Aug. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 05, 2018 |